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Craniopharyngiomas are slow growing benign tumors of the sellar and parasellar region
with an overall incidence rate of approximately 1.3 per million. During adulthood there is
a peak incidence between 40 and 44 years. There are two histopathological types, the
adamantinomatous and the papillary type. The later type occurs almost exclusively in
adult patients. The presenting symptoms develop over years and display a wide spectrum
comprising visual, endocrine, hypothalamic, neurological, and neuropsychological mani-
festations. Currently, the main treatment option consists in surgical excision followed by
radiation therapy in case of residual tumor. Whether gross total or partial resection should
be preferred has to be balanced on an individual basis considering the extent of the tumor
(e.g., hypothalamic invasion). Although the overall long-term survival is good it is often
associated with substantial morbidity. Preexisting disorders are often permanent or even
exacerbated by treatment. Endocrine disturbances need careful replacement and meta-
bolic sequelae should be effectively treated. Regular follow-up by a multidisciplinary team
is a prerequisite for optimal outcome of these patients.
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INTRODUCTION
Craniopharyngiomas are rare benign tumors derived from cell
remnants of Rathke’s pouch along a line from the nasophar-
ynx to the diencephalon. The majority of these epithelial tumors
occur in the sellar, para-, and suprasellar region (Jane and Laws,
2006; Karavitaki et al., 2006; Garnett et al., 2007). In the United
States, craniopharyngiomas constitute approximately 2.5–3% of
brain tumors with an incidence rate (IR) of 1.1–1.3 per mil-
lion (Bunin et al., 1998; Jane and Laws, 2006; Karavitaki et al.,
2006). In other parts of the world, like Japan or certain parts
of Africa, IR seem to be higher (Stiller and Nectoux, 1994). A
recent analysis calculated a worldwide overall IR of 1.34 in all ages
(Nielsen et al., 2011). About half of the cases occur in adults with a
peak IR between 40 and 44 years according to data from a Danish
study (Nielsen et al., 2011). The male to female ratio is 1.1–1.4:1
(Nielsen et al., 2011). Although craniopharyngiomas are regarded
as benign tumors they often inﬁltrate adjacent structures like the
pituitary, hypothalamus, optic nerves, blood vessels, or the third
ventricle thereby causing signiﬁcant morbidity and mortality. As
a consequence patients present with a wide range of symptoms
which are often permanent or might even be exacerbated by
therapy. Because of their inﬁltrative growth behavior and their
high tendency for recurrence, the treatment is often challenging.
In the present article we present an overview on craniopharyn-
giomas with special emphasis on patients with adult-onset of the
disease.
PATHOLOGY AND PATHOGENESIS
Craniopharyngiomas are divided in two main histological sub-
types, the adamantinomatous and the papillary type, but transi-
tional and mixed variants have also been reported (Weiner et al.,
1994; Crotty et al., 1995; Louis et al., 2007). The adamantino-
matous type may develop at all ages, whereas the papillary type
almost exclusively occurs in adults comprising about 14–50% of
the tumors in this age group (Adamson et al., 1990; Weiner et al.,
1994; Karavitaki et al., 2006). The papillary type rarely presents
with calciﬁcations, is generally well-circumscribed and compared
to the adamantinomatous type tumor inﬁltration of surrounding
tissue is less frequent (Weiner et al., 1994; Crotty et al., 1995).
Macroscopically craniopharyngiomas are predominantly cystic or
mixed lesions although solid lesion might also occur. The tumor
size varies from small, solid, and well-circumscribed tumors to
large multilocular cysts invading the sella turcica and displac-
ing adjacent cerebral structures (Crotty et al., 1995; Karavitaki
et al., 2005). Most tumors are located in the sellar/parasellar
region with suprasellar tumor mass extension. A smaller num-
ber of tumors are conﬁned to the sella, or arise in the third
ventricle or within the optic system (Van Effenterre and Boch,
2002).
The molecular pathogenesis of craniopharyngiomas remains
widely unknown. In patients harboring the adamantinomatous
variant mutations in the beta-catenin gene CTNNB1 resulting
in degradation-resistant mutant forms of beta-catenin have been
identiﬁed (Sekine et al., 2002; Kato et al., 2004; Buslei et al.,
2005; Campanini et al., 2010). Studies in rodents showed that
permanent activation of the Wnt signaling pathway, which leads
to high expression levels of beta-catenin, causes formation of
pituitary tumors that resemble the human adamantinomatous
craniopharyngioma. Thus, reactivation of theWnt signaling path-
way may be one factor in the pathogenesis of craniopharyngiomas
of the adamantinomatous type (Gaston-Massuet et al., 2011). The
formation of cysts and their size appears to be associated with the
expression of carbonic anhydrase IX, an enzyme causing ﬂuid pro-
duction. The speciﬁc tumor-associated regulating mechanisms,
however, of this enzyme have not been clariﬁed yet (Proescholdt
et al., 2011).
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CLINICAL MANIFESTATION
The clinical manifestations are multiple and depend on the loca-
tion of the tumor, its size, growth pattern, and relationship to
adjacent cerebral structures (Table 1). As craniopharyngiomas are
in general slowly growing, symptoms may develop gradually –
a circumstance which may contribute to the reported delay of
1–2 years between symptom onset and diagnosis (Garnett et al.,
2007). In adults the most common presenting clinical symp-
toms are visual ﬁeld deﬁcits and signs of hypopituitarism (Hoff
and Patterson, 1972). In about 40–80% of the patients suprasel-
lar tumor extension pressurizes the optic chiasm causing loss of
visual acuity and visual ﬁeld abnormalities (mostly asymmetric
bitemporal hemianopsia; Crotty et al., 1995; Karavitaki et al.,
2005, 2006). In a series of 78 adult patients 57% of the female
patients reported about menstrual irregularities or amenorrhea
and 28% complained about impaired sexual function (Karavitaki
et al., 2005). Other symptoms like nausea and vomiting (26%),
poor energy (32%), and lethargy (26%) are also frequent in the
adult patient (Karavitaki et al., 2005). These symptoms are indica-
tive for anterior pituitary dysfunction. Overall, growth hormone
(GH) deﬁciency is most common, followed by gonadotropin,
adrenocorticotropic hormone (ACTH), and thyroid stimulating
hormone (TSH) deﬁciency, which are present in 86, 74, 58, and
42% of adult cases, respectively (Karavitaki et al., 2005). Com-
pression of the pituitary stalk causes diabetes insipidus (DI) with
polyuria and polydipsia in 17–38.5% of cases (Karavitaki et al.,
2005; Mortini et al., 2011). Hypothalamic involvement may cause
signiﬁcant weight gain, which is a presenting symptom in 13–
15.4% of adult patients (Karavitaki et al., 2005; Mortini et al.,
2011). Severe headaches are also frequent (56%) and may be
caused by raised intracranial pressure due to the tumor mass
itself, to obstructive hydrocephalus resulting from compression of
the third ventricle or due to leaked out cyst content which could
lead to meningeal irritation (Karavitaki et al., 2006). Parasellar
tumor extension with inﬁltration of the cavernous sinus could
result in cranial nerve palsies with diplopia and paresis of ocular
muscles. Involvement of the temporal lobe might trigger seizures
and especially in the elderly, large tumors may cause deteriorat-
ing cognitive abilities and personality changes (Karavitaki et al.,
2006).
Table 1 | Presenting symptoms and clinical manifestations of adults with craniopharyngioma.
Cause Symptom Percentage
Compression of the pituitary
stalk or the pituitary gland
GH deﬁciency 86% (Karavitaki et al., 2005)
FSH/LH deﬁciency 74% (Karavitaki et al., 2005) to 75.6% (Mortini et al., 2011)
ACTH deﬁciency 51.3% (Mortini et al., 2011) to 58% (Karavitaki et al., 2005)
TSH deﬁciency 42% (Karavitaki et al., 2005) to 48.7% (Mortini et al., 2011)
Hyperprolactinemia 30.8% (Mortini et al., 2011) to 55% (Karavitaki et al., 2005)
Galactorrhoea 8% (Karavitaki et al., 2005)
Menstrual disorders 57% (Karavitaki et al., 2005)
Reduction or loss of sexual drive 28% (Karavitaki et al., 2005) to 42% (Crotty et al., 1995)
Cold intolerance 8% (Karavitaki et al., 2005)
Pressure on the optic nerves Visual ﬁeld defects 60% (Karavitaki et al., 2005), 80.8% (Mortini et al., 2011), 84% (Crotty et al., 1995)
Decreased visual acuity 40% (Karavitaki et al., 2005)
Optic atrophy 14% (Karavitaki et al., 2005)
Blindness 3% (Karavitaki et al., 2005)
Hypothalamic involvement Weight gain/hyperphagia 13% (Karavitaki et al., 2005) to 15.4% (Mortini et al., 2011)
Diabetes insipidus 17% (Karavitaki et al., 2005) to 38.5% (Mortini et al., 2011)
Polyuria/polydipsia 15% (Karavitaki et al., 2005) to 27% (Crotty et al., 1995)
Other causes Personality changes 8% (Karavitaki et al., 2005)
Headache 56% (Karavitaki et al., 2005) to 68% (Crotty et al., 1995)
Somnolence 10% (Karavitaki et al., 2005)
Nausea and vomiting 26% (Karavitaki et al., 2005)
Loss of energy 32% (Karavitaki et al., 2005) to 48% (Crotty et al., 1995)
Lethargy 26% (Karavitaki et al., 2005)
Other cranial nerves palsies 9% (Karavitaki et al., 2005)
Papilledema 6% (Karavitaki et al., 2005)
Cognitive impairment 17% (Karavitaki et al., 2005) to 22% (Crotty et al., 1995)
Anorexia/weight loss 8% (Karavitaki et al., 2005)
Decreased consciousness/coma 4% (Karavitaki et al., 2005)
Unsteadiness/ataxia 3% (Karavitaki et al., 2005)
Hemiparesis 1% (Karavitaki et al., 2005)
Meningitis 3% (Karavitaki et al., 2005)
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DIAGNOSIS
The suspicion of a craniopharyngioma is based on clinical and
radiological ﬁndings. The diagnosis is ﬁnally proven by histology.
A proposal for the initial diagnostic work-up in patients suspicious
for craniopharyngioma is given in Table 2.
Most adult patients present with visual ﬁeld deﬁcits and signs
of hypopituitarism (Hoff and Patterson, 1972). Visual ﬁeld and
visual acuity assessment is therefore important to determine any
deﬁcit and to establish baseline values. In addition, an examina-
tion of the optic disks is required to rule out papilledema and
visual evoked potentials are recommended. An endocrine eval-
uation should include the assessment of anterior and posterior
pituitary functions. Signs and symptoms indicative for hypopitu-
itarism including DI should be asked for. Basal ACTH and cortisol,
TSH and free T4, LH and testosterone in men and FSH and estra-
diol in women, IGF-1 and prolactin as well as serum electrolytes,
serum, and urine osmolality are determined. Further endocrine
testings should be performed according to the results and the
individual clinical situation.
Cranial computer tomography (CT) and/or magnetic reso-
nance imaging (MRI) with and without contrast enhancement are
part of the neuroradiological evaluation of craniopharyngiomas.
Calciﬁcations and bony structures are best evaluated on CT, while
the delineation of tumor size and the involvement of neighbor-
ing structures can be assessed most accurately by MRI. The MRI
scan is therefore the method of choice in order to prepare a sur-
gical approach (Garnett et al., 2007). According to a recent study,
there are no signiﬁcant differences in neuroradiological charac-
teristics of craniopharyngiomas between children and adults with
the exception of lower rates of tumor calciﬁcation in adult patients
(Mortini et al., 2011). In some studies hydrocephalus occurred
less frequently in adults than in children, however other authors
reported no differences in this regard (Van Effenterre and Boch,
Table 2 | Diagnostic work-up of patients with craniopharyngioma.
Anamnesis Visual ﬁeld deﬁcits, loss of visual acuity?
Loss of libido, amenorrhea?
Polyuria, polydipsia?
Headaches?
Nausea, vomiting?
Weight gain?
Fatigue, tiredness
Sleep disorders?
Concentration deﬁcits?
Cold intolerance?
Neuroimaging MRI
CT
Laboratory tests IGF-1, prolactin, ACTH, cortisol, TSH, fT4,
LH, FSH, testosterone ( )/estradiol ( ) serum
electrolytes, serum-osmolality, urine
osmolality
Ophthalmological evaluation Visual acuity testing
Visual ﬁeld perimetry
Optic disks evaluation (visual evoked
potentials)
2002; Karavitaki et al., 2005). Although several attempts have been
made,no reliable discrimination between the two histological sub-
types is possible based on neuroradiological criteria (Crotty et al.,
1995; Eldevik et al., 1996; Sartoretti-Schefer et al., 1997). In some
cases the presence of a craniopharyngioma is suggested by an
incidental ﬁnding of a mass lesion on neuroimaging scans. The
differential diagnosis comprises other sellar and parasellar tumors
like Rathke’s cleft cysts and other non-malignant cysts, pitu-
itary adenomas, optic and hypothalamic gliomas, meningiomas,
teratomas, germinomas, lymphomas, metastases, and inﬁltrative
diseases, like sarcoidosis or systemic histiocytosis (Garnett et al.,
2007).
TREATMENT
Prospective and controlled studies comparing different treatment
strategies in adult patients aremissing.Most data come from retro-
spective analyses of mixed populations of patients with childhood-
and adult-onset disease. There are no evidence-based guidelines
or a clear consensus for best treatment of primary or recur-
rent craniopharyngiomas in adults. Like in children a radical
approach with complete tumor resection and potential cure has to
be balanced with a more conservative approach to avoid substan-
tial treatment-associated long-term morbidity. Therefore, optimal
treatment should always be individualized taking into account,
e.g., the patient’s symptoms, age, tumor localization, and exten-
sion. Endocrine and metabolic complications should be treated
prior to any tumor-directed therapy such as surgery. This is espe-
cially important in case of adrenal or thyroidal insufﬁciency, as
well as DI. It is generally agreed that a multidisciplinary team
comprising endocrinologists, neurosurgeons, radiotherapists, and
ophthalmologists is essential for optimized treatment of patients
of any age (Garnett et al., 2007; Garre and Cama, 2007; Honegger
and Tatagiba, 2008).
SURGERY
Surgery is theﬁrst-line approach to the treatmentof craniopharyn-
giomas. Complete surgical resection is the goal of initial therapy
and because of major advances in neurosurgical techniques, it is
increasingly feasible. However, due to their size, their often irreg-
ular margins and intense peritumoral gliosis with adherence to
vital neighboring neurovascular structures this is often difﬁcult
and potentially dangerous. According to the literature complete
tumor removal by radical surgery can be achieved in 18–84% of
selected childhood and adult cases (Weiner et al., 1994; Fahlbusch
et al., 1999; Van Effenterre and Boch, 2002; Karavitaki et al., 2005,
2006). Aggressive surgery with gross total resection (GTR) of the
tumor,however,may result in signiﬁcant and devastating peri- and
postoperativemorbidity especially after resectionof tumors invad-
ing the hypothalamus (Rutka, 2002). If complete tumor removal
is unlikely to be achieved or too hazardous, subtotal, or partial
resection (PR) of the tumor, e.g., to reduce pressure effects on
adjacent structures like the optic pathways and/or to re-establish
circulation of the cerebrospinal ﬂuid with or without subsequent
radiotherapy is an alternative approach (Habrand et al., 1999;
Cama et al., 2006). In any case the beneﬁts of surgery must be
balanced against the risks of treatment-related morbidity. For
pediatric patients a preoperative grading systemhas beenproposed
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according to the degree of hypothalamic involvement (Puget et al.,
2007). Using this classiﬁcation a signiﬁcant relationship between
the preoperative tumor grade and post-surgical morbidity could
be demonstrated. GTR should only be attempted in patients
without hypothalamic involvement (grade 0) or with a distorted
or elevated but still visible hypothalamus (grade 1). In grade 2
craniopharyngiomas (hypothalamic structures not discernible) a
subtotal resection leaving the hypothalamic part is recommended
(Puget et al., 2007). Similar studies in adults are lacking. Nev-
ertheless it appears reasonable to follow these recommendations
established in pediatric patients. For craniopharyngiomas with
major cystic portions stereotactic cyst decompression is another
treatment option. This can be used for acute symptomatic therapy,
prior to deﬁnite craniopharyngioma resection, or may be recom-
mended as intermittent therapy whenever a total cyst excision
is not possible (Fahlbusch et al., 1999; Honegger and Tatagiba,
2008).
RADIOTHERAPY
Radiotherapy (RT) is a therapeutic option in patients for whom
surgery is contraindicated,with residual tumor tissue after subtotal
or partial surgical resection, as well as in patients with recur-
rent disease. Advances in RT techniques allow higher treatment
precision with less long-term toxicity by focusing the ionizing
radiation on the tumor and limiting the exposure of adjacent
tissues to a minimum. Techniques used for the treatment of cran-
iopharyngiomas include stereotactic fractionated radiotherapy,
radiosurgery, intensity modulated radiation therapy, and proton
beam therapy (Fitzek et al., 2006; Minniti et al., 2009; Niran-
jan et al., 2010). For fractionated conformal RT schedules the
probability of local tumor control is best with radiation doses
above 54–55 Gy (Regine et al., 1993) but less than 61 Gy to
lower the risk of radiation-associated side-effects such as visual
impairment, pituitary deﬁciency, impaired cognitive function or
development of secondary malignancies (Cavazzuti et al., 1983;
Merchant et al., 2006). Application of radiosurgery with deliv-
ery of a single high-dose radiation to the tumor is an attractive
technique but restricted to smaller tumor volumes and requires
sufﬁcient safety margins of adjacent critical structures. Although
reports published so far are promising (Minniti et al., 2009;
Iwata et al., 2012), further studies are needed to deﬁne its role
in the prevention of tumor recurrence and its potential long-
term adverse effects. Intracavitary irradiation with stereotactically
guided instillation of radioisotopes is another approach to treat
mono- or multicystic tumors (Voges et al., 1997; Barriger et al.,
2011).
OTHER TREATMENTS
Other treatment options for predominantly cystic craniopharyn-
giomas comprise intracystic chemotherapy or immunological
therapy with bleomycin or interferon alpha, respectively (Stein-
bok and Hukin, 2010). The experience regarding these treat-
ments is mainly restricted to pediatric patients. In general, these
options were used for temporary tumor control with the expec-
tation for further therapies like surgery or radiotherapy. Systemic
chemotherapy is generally regarded as ineffective (Karavitaki et al.,
2006).
RECURRENT DISEASE
Recurrence of craniopharyngiomas remains a problem which
highly impacts on the long-term prognosis of the patients. In a
recent study with 106 patients including 78 adults, 24.5% experi-
enced a relapse within a median follow-up of 83 months (Mortini
et al., 2011). The risk of recurrence appears highest in the ﬁrst
3 years after surgery and then tends to reach a plateau (Fahlbusch
et al., 1999; Karavitaki et al., 2005). After GTR the risk of tumor
recurrence has been reported to range between 0 and 26% (Maira
et al., 1995; Fahlbusch et al., 1999; Duff et al., 2000). This is sig-
niﬁcantly lower than in patients with subtotal or partial tumor
resection in whom tumor recurrence occurs in 25–100% of the
patients (Fahlbusch et al., 1999; Duff et al., 2000; Karavitaki et al.,
2005). In these patients adjuvant RT signiﬁcantly improves the
tumor control rates with recurrence rates ranging from 10 to 63%
at 10-years follow-up (Karavitaki et al., 2006). Thus, patients with
subtotal resection without subsequent RT have the highest risk of
relapse (Duff et al., 2000;Karavitaki et al., 2005). In patients treated
with RT alone tumor growth or recurrence was observed in 0–23%
of the patients at 10 years follow-up (Hetelekidis et al., 1993; Rajan
et al., 1993). The data about the prognostic signiﬁcance of age at
diagnosis, gender, tumor size, location, or consistency, as well as
the histological subtype are inconsistent (Karavitaki et al., 2005,
2006; Mortini et al., 2011), but in general these factors do not seem
to affect the risk of recurrence (Karavitaki et al., 2006).
TREATMENT OF RECURRENT DISEASE
Recurrent disease is difﬁcult to treat. Because of scars and adhe-
sions due to previous surgery or radiation, the surgical success
rates for recurrent disease are signiﬁcantly lower than for primary
surgery andperi- andpostoperativemorbidity andmortality is sig-
niﬁcantly increased (Yasargil et al., 1990; Wisoff, 1994; Fahlbusch
et al., 1999; Karavitaki et al., 2005). Therefore, the severity of
clinical symptoms has to be taken into account and it has been sug-
gested that repeated surgery should only be performed when acute
pressure effects occur (Karavitaki et al., 2006). In patients not pre-
viously treated with RT irradiation is another option either instead
of or following a second surgery, and it appears that RT is equally
effective in the control of recurrent tumors as for primary treat-
ment (Jose et al., 1992). Further options comprise cyst controlling
procedures like aspiration, intracystic irradiation or application of
bleomycin, salvage surgery in case of life-threatening solid lesions,
or radiosurgery. In any case treatment decisions for recurrent
disease should be made on an individualized basis.
DISEASE AND TREATMENT COMPLICATIONS
ENDOCRINE
Anterior pituitary dysfunction and DI are common in adult
patients with craniopharyngiomas and the majority of adult cran-
iopharyngioma patients present with signs and symptoms of
hypopituitarism (Paja et al., 1995; Honegger et al., 1999; Karavi-
taki et al., 2005). Neuroendocrine dysfunction may worsen upon
treatment. In a recent study by Mortini et al. (2011) 82.3, 75.9,
72.7, and 66.7% of patients with normal baseline values for GH,
ACTH, TSH, and gonadotropins developed a new deﬁciency of
the respective pituitary axis after surgery. Post-surgical onset of
DI was observed in 69.6% of their patients. The risk for new
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hormone deﬁciencies appears to be lower after transsphenoidal
operation (Honegger et al., 1999; Mortini et al., 2011). In contrast
to pituitary adenomas, recovery of preexisting pituitary dysfunc-
tion after surgery is rare (Webb et al., 1999; Mortini et al., 2011).
Although symptomatic DI appears to occur more frequent in sur-
gically treated patients (Hetelekidis et al., 1993; Karavitaki et al.,
2006), long-term endocrine morbidity in general seems not to be
affected by the type of therapy (Weiner et al., 1994; Habrand et al.,
1999; Karavitaki et al., 2005). Most of the patients chronically suf-
fer from partial or complete hypopituitarism as well as DI, with
approximately 80% requiring the substitution of more than two
hormones (Kendall-Taylor et al., 2005; Verhelst et al., 2005). Con-
cerning GH substitution, observational studies suggest that GH
replacement does not increase the risk of tumor recurrence (Abs
et al., 1999). Because of the often complex endocrine morbidity
lifelong surveillance by an endocrinologist is required.
VISUAL
In adults impaired visual function is common at ﬁrst presentation
(Crotty et al., 1995; Karavitaki et al., 2005, 2006). After surgical
decompression visual deﬁcits often improve, but may also remain
unchanged or even become worse (Fahlbusch et al., 1999; Van
Effenterre and Boch, 2002; Mortini et al., 2011). In a series of 173
patients treated with RT only or after limited surgery, improve-
ment in visual ﬁeld defects or in visual acuity was observed in 36
and 30%, respectively after a median follow-up of 12 years (Rajan
et al., 1993). In about one-third of the patients pretreatment visual
deﬁcits deteriorated (Rajan et al., 1993). No radiation optic neu-
ropathy developed by applying accurate RT techniques and doses
below the tolerance limit of the optic system (Harris and Lev-
ene, 1976; Rajan et al., 1993). Karavitaki et al. (2005) reported
in their series of patients with long-term follow-up about major
visual ﬁeld defects in 49 and 72% of the patients after 10 and
20 years, respectively. This reﬂects treatment-associated deteriora-
tion of visual function on the one hand and on the other hand the
natural course of the disease with a high risk for recurrence. Risk
factors for adverse visual outcome are the presence of visual symp-
toms at diagnosis, irradiation dose above 2 Gy per day, and a PR
of the tumor, probably because of the increased risk of recurrence
(Harris and Levene, 1976; Karavitaki et al., 2005, 2006). Long-term
follow-up by an ophthalmologist is recommended.
HYPOTHALAMIC AND METABOLIC
Tumor- or treatment-related damage of the ventromedial hypo-
thalamus may lead to the impairment of mechanisms control-
ling satiety, hunger, and energy expenditure resulting in severe
obesity (Daousi et al., 2005). Hypothalamic obesity is the most
common manifestation of hypothalamic complications. At pre-
sentation about 15% of adult patients complain about excessive
weight gain or are obese (Karavitaki et al., 2005; Mortini et al.,
2011). During long-time follow-up excessive weight gain has been
reported in up to 67% of patients after surgery with and with-
out adjuvant RT (Hoffman et al., 1992; Karavitaki et al., 2005).
Hypothalamic obesity is often associated with disastrous meta-
bolic and psychological consequences leading to severe morbidity,
impaired quality of life, and reduced life expectancy (Karavitaki
et al., 2006). Features of the metabolic syndrome like abdominal
obesity, dyslipidemia, hyperinsulinemia caused by insulin resis-
tance, and elevated blood pressure are commonly seen in patients
with craniopharyngiomas (Kendall-Taylor et al., 2005; Pereira
et al., 2005;Holmer et al., 2009). In a retrospective analysis from the
KIMS database patients with adult-onset disease were more obese,
had a greater waist circumference, and had higher cholesterol
and triglycerides levels with similar HDL- and LDL-cholesterol
when compared to patients with childhood disease onset (Kendall-
Taylor et al., 2005). Together, these metabolic alterations increase
the risk of hypertension, diabetes, and atherosclerosis, which all
lead to cardiovascular disease and mortality from vascular events
(Van Gaal et al., 2006). Thus, the necessity for treatment is vital
but treatment of hypothalamic obesity is difﬁcult and patients
need to comply with dietary and behavioral modiﬁcations com-
prising regular physical activities, require anti obesity drugs, or
even bariatric surgery (Karavitaki et al., 2006). DI with an absent
sense of thirst is another hypothalamic complication resulting in
serious water and electrolyte imbalances, which was observed in
19% of adult patients after surgery with and without adjuvant
RT (Smith et al., 2004). Sleep disorders and increased daytime
somnolence caused by disruption of the circadian rhythm occur
in up to one-third of adult craniopharyngioma patients (van der
Klaauw et al., 2008). Impaired thermoregulation with hyper- or
hypothermia has also been observed in adults (Lipton et al., 1981;
Grifﬁths et al., 1988). Risk factors for hypothalamic complications
are preexisting disorders at diagnosis, young age at presentation
of symptoms, hypothalamic invasion, tumor size, multiple oper-
ations due to recurrence, and hypothalamic radiation with doses
above 51 Gy (de Vile et al., 1996; Lustig et al., 2003; Poretti et al.,
2004).
NEUROPSYCHOLOGICAL AND COGNITIVE DYSFUNCTION
Behavioral problems and deteriorated cognitive functions are rel-
atively common, which contribute to decreased academic and
occupational performance, difﬁculties in maintaining family, and
social relationships, resulting in a loss in quality of life (Cavazzuti
et al., 1983; Karavitaki et al., 2006).
OTHERS
In patients who received RT vascular damage like aneurysms and
secondary brain tumors may occur (Enchev et al., 2009; Liu et al.,
2009).
LONG-TERM PROGNOSIS AND MORTALITY
Control of tumor growth and the disease- or treatment-related
complications determine the long-term prognosis. Overall sur-
vival rates reported range from 89 to 94% at 5-years and from 85
to 90% at 10-years follow-up (Van Effenterre and Boch, 2002; Kar-
avitaki et al., 2005). Nevertheless, overall mortality appears three
to ﬁve times higher than those of the general population (Sher-
lock et al., 2010). Currently, it is unclear which therapeutic strategy
(e.g., GTR or subtotal or PR followed by radiotherapy) is associ-
ated with a better survival (Karavitaki et al., 2005; Sherlock et al.,
2010) and whether the histological subtype is of relevance (Weiner
et al., 1994). Recurrent disease, however, is signiﬁcantly associated
with increased morbidity and mortality, resulting in lower 10-
year survival rates (29–70%; Karavitaki et al., 2005; Honegger and
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Tatagiba, 2008). Apart from mortality caused by the tumor itself
or by surgical treatment, mortality from cardio- and cerebrovas-
cular as well as respiratory causes is increased (Bulow et al., 1998;
Tomlinson et al., 2001). It is therefore essential to optimize the
treatment of any endocrine and metabolic sequelae of the disease
in order to reduce mortality in this high risk patient population.
CONCLUSION
Although craniopharyngiomas are generally benign their loca-
tion, size, and tendency to inﬁltrate adjacent cerebral structures
makes theirmanagement rather demanding andmay lead to some-
times devastating complications. According to the data available
adult- and childhood-onset craniopharyngiomas behave similar in
many aspects. Treatment decisions for primary or recurrent dis-
ease need to consider long-term tumor control as well as disease
and treatment-related morbidity and they are often reached on
an individualized basis. Surgery is the initial treatment approach,
which should remove as much tumor as safely possible, while
avoiding severe treatment-induced complications. There is some
controversy as to whether a more radical surgical approach with
gross total tumor resection should be aimed at or a more limited
approach with reducing the tumor mass followed by radiother-
apy in order to minimize long-term morbidity. As some patients
with subtotal or partial tumor resection may have stable disease
and since RT may cause long-term complications it is currently
unclear, whether all patients with residual tumor should receive
immediate postoperative RT. Likewise it is unknown which ther-
apeutic strategy is best in patients with tumor recurrence despite
RT. Posttreatment follow-up should include neuroimaging with
MRI, visual assessment, and monitoring of endocrine functions
and metabolic status. Endocrine and metabolic alterations need
to be treated adequately. There is no doubt that for optimal results
a lifelong surveillance of an experienced multidisciplinary team is
essential.
ACKNOWLEDGMENTS
This work was supported by the Emerging Field Initiative
“Neurotrition” of the Friedrich-Alexander University Erlangen-
Nuremberg, Germany. We thank Dr. Joseﬁne Römmler for critical
reading of the manuscript and her valuable comments.
REFERENCES
Abs, R., Bengtsson, B. A., Hernberg-
Stahl, E., Monson, J. P., Tauber,
J. P., Wilton, P., and Wuster, C.
(1999). GH replacement in 1034
growth hormone deﬁcient hypopi-
tuitary adults: demographic and
clinical characteristics, dosing and
safety. Clin. Endocrinol. (Oxf.) 50,
703–713.
Adamson, T. E., Wiestler, O. D., Klei-
hues, P., and Yasargil, M. G. (1990).
Correlation of clinical and patho-
logical features in surgically treated
craniopharyngiomas. J. Neurosurg.
73, 12–17.
Barriger, R. B., Chang, A., Lo, S.
S., Timmerman, R. D., DesRosiers,
C., Boaz, J. C., and Fakiris, A. J.
(2011). Phosphorus-32 therapy for
cystic craniopharyngiomas. Radio-
ther. Oncol. 98, 207–212.
Bulow, B., Attewell, R., Hagmar, L.,
Malmstrom, P., Nordstrom, C. H.,
and Erfurth, E. M. (1998). Postop-
erative prognosis in craniopharyn-
gioma with respect to cardiovascular
mortality, survival, and tumor recur-
rence. J. Clin. Endocrinol. Metab. 83,
3897–3904.
Bunin, G. R., Surawicz, T. S.,Witman, P.
A., Preston-Martin, S., Davis, F., and
Bruner, J. M. (1998). The descrip-
tive epidemiology of craniopharyn-
gioma. J. Neurosurg. 89, 547–551.
Buslei, R., Nolde, M., Hofmann,
B., Meissner, S., Eyupoglu, I. Y.,
Siebzehnrubl, F., Hahnen, E.,
Kreutzer, J., and Fahlbusch, R.
(2005). Common mutations of
beta-catenin in adamantinomatous
craniopharyngiomas but not in
other tumours originating from the
sellar region. Acta Neuropathol. 109,
589–597.
Cama, A., Ravegnani, M., Piatelli, G.,
Rossi, A., Gandolfo, C., and Garre,
M. L. (2006). Conservative surgical
approach in treatment strategy of
craniopharyngioma: experience at a
single institution in Italy. J. Pedi-
atr. Endocrinol. Metab. 19(Suppl. 1),
337–340.
Campanini, M. L., Colli, L. M., Paixao,
B. M., Cabral, T. P., Amaral, F.
C., Machado, H. R., Neder, L.
S., Saggioro, F., Moreira, A. C.,
Antonini, S. R., and de Castro, M.
(2010). CTNNB1 gene mutations,
pituitary transcription factors, and
MicroRNA expression involvement
in the pathogenesis of adamantino-
matous craniopharyngiomas.Horm.
Cancer 1, 187–196.
Cavazzuti, V., Fischer, E. G., Welch,
K., Belli, J. A., and Winston, K.
R. (1983). Neurological and psy-
chophysiological sequelae follow-
ing different treatments of cranio-
pharyngioma in children. J. Neuro-
surg. 59, 409–417.
Crotty, T. B., Scheithauer, B. W., Young,
W. F. Jr., Davis, D. H., Shaw, E.
G., Miller, G. M., and Burger, P.
C. (1995). Papillary craniopharyn-
gioma: a clinicopathological study of
48 cases. J. Neurosurg. 83, 206–214.
Daousi, C., Dunn, A. J., Foy, P. M.,
MacFarlane, I. A., and Pinkney,
J. H. (2005). Endocrine and neu-
roanatomic features associated with
weight gain and obesity in adult
patients with hypothalamic damage.
Am. J. Med. 118, 45–50.
de Vile, C. J., Grant, D. B., Hayward,
R. D., Kendall, B. E., Neville, B. G.,
and Stanhope, R. (1996). Obesity in
childhood craniopharyngioma: rela-
tion to post-operative hypothalamic
damage shown by magnetic reso-
nance imaging. J. Clin. Endocrinol.
Metab. 81, 2734–2737.
Duff, J. M., Mayer, F. B., Ilstrup,
D. M., Laws, E. R. Jr., Scleck, C.
D., and Scheithauer, B. W. (2000).
Long-term outcomes for surgically
resected craniopharyngiomas. Neu-
rosurgery 46, 291–302.
Eldevik, O. P., Blaivas, M., Gabrielsen,
T. O., Hald, J. K., and Chandler, W.
F. (1996). Craniopharyngioma: radi-
ologic and histologic ﬁndings and
recurrence. AJNR Am. J. Neurora-
diol. 17, 1427–1439.
Enchev, Y., Ferdinandov, D., Kounin,
G., Encheva, E., and Bussarsky, V.
(2009). Radiation-induced gliomas
following radiotherapy for cranio-
pharyngiomas: a case report and
review of the literature. Clin. Neurol.
Neurosurg. 111, 591–596.
Fahlbusch, R., Honegger, J., Paulus,
W., Huk, W., and Buchfelder, M.
(1999). Surgical treatment of cran-
iopharyngiomas: experience with
168 patients. J. Neurosurg. 90,
237–250.
Fitzek, M. M., Linggood, R. M.,
Adams, J., and Munzenrider, J. E.
(2006). Combined proton and pho-
ton irradiation for craniopharyn-
gioma: long-term results of the
early cohort of patients treated at
Harvard Cyclotron Laboratory and
Massachusetts General Hospital. Int.
J. Radiat. Oncol. Biol. Phys. 64,
1348–1354.
Garnett, M. R., Puget, S., Grill,
J., and Sainte-Rose, C. (2007).
Craniopharyngioma. Orphanet. J.
Rare Dis. 2, 18.
Garre, M. L., and Cama, A. (2007).
Craniopharyngioma: modern con-
cepts in pathogenesis and treatment.
Curr. Opin. Pediatr. 19, 471–479.
Gaston-Massuet, C., Andoniadou, C.
L., Signore, M., Jayakody, S. A.,
Charolidi, N., Kyeyune, R., Ver-
nay, B., Jacques, T. S., Taketo, M.
M., Le Tissier, P., Dattani, M. T.,
and Martinez-Barbera, J. P. (2011).
Increased Wingless (Wnt) signal-
ing in pituitary progenitor/stem cells
gives rise to pituitary tumors in mice
and humans. Proc. Natl. Acad. Sci.
U.S.A. 108, 11482–11487.
Grifﬁths, A. P., Henderson, M., Penn, N.
D., andTindall,H. (1988).Haemato-
logical, neurological and psychiatric
complications of chronic hypother-
mia following surgery for cranio-
pharyngioma. Postgrad. Med. J. 64,
617–620.
Habrand, J. L., Ganry, O., Couanet, D.,
Rouxel,V., Levy-Piedbois, C., Pierre-
Kahn, A., and Kalifa, C. (1999). The
role of radiation therapy in the man-
agement of craniopharyngioma: a
25-year experience and review of the
literature. Int. J. Radiat. Oncol. Biol.
Phys. 44, 255–263.
Harris, J. R., and Levene, M. B.
(1976).Visual complications follow-
ing irradiation for pituitary adeno-
mas and craniopharyngiomas. Radi-
ology 120, 167–171.
Hetelekidis, S., Barnes, P. D., Tao, M. L.,
Fischer, E. G., Schneider, L., Scott,
R. M., and Tarbell, N. J. (1993). 20-
year experience in childhood cranio-
pharyngioma. Int. J. Radiat. Oncol.
Biol. Phys. 27, 189–195.
Frontiers in Endocrinology | Pituitary Endocrinology March 2012 | Volume 3 | Article 46 | 6
Zoicas and Schöﬂ Craniopharyngiomas in adults
Hoff, J. T., and Patterson, R. H.
Jr. (1972). Craniopharyngiomas in
children and adults. J. Neurosurg. 36,
299–302.
Hoffman, H. J., De Silva, M.,
Humphreys, R. P., Drake, J. M.,
Smith, M. L., and Blaser, S. I. (1992).
Aggressive surgical management of
craniopharyngiomas in children. J.
Neurosurg. 76, 47–52.
Holmer, H., Ekman, B., Bjork, J., Nord-
stom, C. H., Popovic, V., Siversson,
A., and Erfurth, E. M. (2009). Hypo-
thalamic involvement predicts car-
diovascular risk in adults with child-
hood onset craniopharyngioma on
long-term GH therapy. Eur. J.
Endocrinol. 161, 671–679.
Honegger, J., Buchfelder, M., and
Fahlbusch, R. (1999). Surgical
treatment of craniopharyn-
giomas: endocrinological results. J.
Neurosurg. 90, 251–257.
Honegger, J., and Tatagiba, M. (2008).
Craniopharyngioma surgery. Pitu-
itary 11, 361–373.
Iwata, H., Tatewaki, K., Inoue, M.,
Yokota, N., Baba, Y., Nomura, R.,
Shibamoto, Y., and Sato, K. (2012).
Single and hypofractionated stereo-
tactic radiotherapy with CyberKnife
for craniopharyngioma. J. Neuroon-
col. 106, 571–577.
Jane, J. A. Jr., and Laws, E. R. (2006).
Craniopharyngioma. Pituitary 9,
323–326.
Jose, C. C., Rajan, B., Ashley, S., Marsh,
H., andBrada,M. (1992). Radiother-
apy for the treatment of recurrent
craniopharyngioma. Clin. Oncol. (R.
Coll. Radiol.) 4, 287–289.
Karavitaki, N., Brufani, C.,Warner, J. T.,
Adams, C. B., Richards, P., Ansorge,
O., Shine,B., Turner,H. E., andWass,
J. A. (2005). Craniopharyngiomas
in children and adults: systematic
analysis of 121 cases with long-term
follow-up. Clin. Endocrinol. (Oxf.)
62, 397–409.
Karavitaki, N., Cudlip, S., Adams, C.
B., and Wass, J. A. (2006). Cran-
iopharyngiomas. Endocr. Rev. 27,
371–397.
Kato, K., Nakatani, Y., Kanno, H.,
Inayama, Y., Ijiri, R., Nagahara, N.,
Miyake, T., Tanaka, M., Ito, Y., Aida,
N., Tachibana, K., Sekido, K., and
Tanaka, Y. (2004). Possible linkage
between speciﬁc histological struc-
tures and aberrant reactivation of
the Wnt pathway in adamantinoma-
tous craniopharyngioma. J. Pathol.
203, 814–821.
Kendall-Taylor, P., Jonsson, P. J., Abs,
R., Erfurth, E. M., Koltowska-
Haggstrom, M., Price, D. A., and
Verhelst, J. (2005). The clinical,
metabolic and endocrine features
and the quality of life in adults
with childhood-onset cranio-
pharyngioma compared with
adult-onset craniopharyngioma.
Eur. J. Endocrinol. 152, 557–567.
Lipton, J. M., Rosenstein, J., and Sklar,
F. H. (1981). Thermoregulatory dis-
orders after removal of a cranio-
pharyngioma from the third cerebral
ventricle. Brain Res. Bull. 7, 369–373.
Liu, A. K., Bagrosky, B., Fenton, L.
Z., Gaspar, L. E., Handler, M.
H., McNatt, S. A., and Foreman,
N. K. (2009). Vascular abnormal-
ities in pediatric craniopharyn-
gioma patients treated with radia-
tion therapy. Pediatr. Blood Cancer
52, 227–230.
Louis, D. N., Ohgaki, H.,Wiestler, O. D.,
Cavenee,W. K., Burger, P. C., Jouvet,
A., Scheithauer, B. W., and Kleihues,
P. (2007). The 2007 WHO classiﬁca-
tion of tumours of the central ner-
vous system. Acta Neuropathol. 114,
97–109.
Lustig, R. H., Post, S. R., Srivanna-
boon, K., Rose, S. R., Danish, R.
K., Burghen, G. A., Xiong, X., Wu,
S., and Merchant, T. E. (2003).
Risk factors for the development of
obesity in children surviving brain
tumors. J. Clin. Endocrinol. Metab.
88, 611–616.
Maira, G., Anile, C., Rossi, G. F., and
Colosimo, C. (1995). Surgical treat-
ment of craniopharyngiomas: an
evaluation of the transsphenoidal
and pterional approaches. Neuro-
surgery 36, 715–724.
Merchant, T. E., Kiehna, E. N., Kun, L.
E., Mulhern, R. K., Li, C., Xiong,
X., Boop, F. A., and Sanford, R.
A. (2006). Phase II trial of con-
formal radiation therapy for pedi-
atric patients with craniopharyn-
gioma and correlation of surgical
factors and radiation dosimetrywith
change in cognitive function. J. Neu-
rosurg. 104, 94–102.
Minniti, G., Esposito, V., Amichetti, M.,
and Enrici, R. M. (2009). The role
of fractionated radiotherapy and
radiosurgery in the management of
patients with craniopharyngioma.
Neurosurg. Rev. 32, 125–132.
Mortini, P., Losa, M., Pozzobon, G.,
Barzaghi, R., Riva, M., Acerno, S.,
Angius,D.,Weber,G.,Chiumello,G.,
and Giovanelli, M. (2011). Neuro-
surgical treatment of craniopharyn-
gioma in adults and children: early
and long-term results in a large case
series. J. Neurosurg. 114, 1350–1359.
Nielsen, E. H., Feldt-Rasmussen, U.,
Poulsgaard, L., Kristensen, L. O.,
Astrup, J., Jorgensen, J. O., Bjerre,
P., Andersen, M., Andersen, C.,
Jorgensen, J., Lindholm, J., and
Laurberg, P. (2011). Incidence of
craniopharyngioma in Denmark (n
= 189) and estimated world inci-
dence of craniopharyngioma in chil-
dren and adults. J. Neurooncol. 104,
755–763.
Niranjan, A., Kano, H., Mathieu, D.,
Kondziolka, D., Flickinger, J. C.,
and Lunsford, L. D. (2010). Radio-
surgery for craniopharyngioma. Int.
J. Radiat. Oncol. Biol. Phys. 78,
64–71.
Paja, M., Lucas, T., Garcia-Uria, J.,
Salame, F., Barcelo, B., and Estrada,
J. (1995). Hypothalamic-pituitary
dysfunction in patients with cran-
iopharyngioma. Clin. Endocrinol.
(Oxf.) 42, 467–473.
Pereira,A. M., Schmid, E. M., Schutte, P.
J., Voormolen, J. H., Biermasz, N. R.,
vanThiel, S.W.,Corssmit,E. P., Smit,
J. W., Roelfsema, F., and Romijn,
J. A. (2005). High prevalence of
long-term cardiovascular, neurolog-
ical and psychosocialmorbidity after
treatment for craniopharyngioma.
Clin. Endocrinol. (Oxf.) 62, 197–204.
Poretti, A., Grotzer, M. A., Ribi,
K., Schonle, E., and Boltshauser,
E. (2004). Outcome of cranio-
pharyngioma in children: long-
term complications and quality of
life. Dev. Med. Child Neurol. 46,
220–229.
Proescholdt, M., Merrill, M., Stoerr,
E. M., Lohmeier, A., Dietmaier, W.,
and Brawanski, A. (2011). Expres-
sion of carbonic anhydrase IX in
craniopharyngiomas. J. Neurosurg.
115, 796–801.
Puget, S., Garnett, M., Wray, A., Grill,
J., Habrand, J. L., Bodaert, N.,
Zerah, M., Bezerra, M., Renier, D.,
Pierre-Kahn, A., and Sainte-Rose,
C. (2007). Pediatric craniopharyn-
giomas: classiﬁcation and treatment
according to the degree of hypothal-
amic involvement. J. Neurosurg. 106,
3–12.
Rajan, B., Ashley, S., Gorman, C., Jose,
C. C., Horwich, A., Bloom, H. J.,
Marsh, H., and Brada, M. (1993).
Craniopharyngioma – a long-term
results following limited surgery and
radiotherapy. Radiother. Oncol. 26,
1–10.
Regine, W. F., Mohiuddin, M., and
Kramer, S. (1993). Long-term results
of pediatric and adult cranio-
pharyngiomas treated with com-
bined surgery and radiation. Radio-
ther. Oncol. 27, 13–21.
Rutka, J. T. (2002). Craniopharyn-
gioma. J. Neurosurg. 97, 1–2; discus-
sion 2.
Sartoretti-Schefer, S., Wichmann, W.,
Aguzzi, A., and Valavanis, A. (1997).
MR differentiation of adamantinous
and squamous-papillary cranio-
pharyngiomas. AJNR Am. J. Neuro-
radiol. 18, 77–87.
Sekine, S., Shibata, T., Kokubu,
A., Morishita, Y., Noguchi, M.,
Nakanishi, Y., Sakamoto, M., and
Hirohashi, S. (2002). Craniopharyn-
giomas of adamantinomatous
type harbor beta-catenin gene
mutations. Am. J. Pathol. 161,
1997–2001.
Sherlock, M., Ayuk, J., Tomlinson, J.
W., Toogood, A. A., Aragon-Alonso,
A., Sheppard, M. C., Bates, A. S.,
and Stewart, P. M. (2010). Mortal-
ity in patients with pituitary disease.
Endocr. Rev. 31, 301–342.
Smith, D., Finucane, F., Phillips,
J., Baylis, P. H., Finucane, J.,
Tormey, W., and Thompson, C.
J. (2004). Abnormal regulation of
thirst and vasopressin secretion fol-
lowing surgery for craniopharyn-
gioma. Clin. Endocrinol. (Oxf.) 61,
273–279.
Steinbok, P., and Hukin, J. (2010).
Intracystic treatments for cran-
iopharyngioma. Neurosurg. Focus
28, E13.
Stiller, C. A., and Nectoux, J.
(1994). International incidence
of childhood brain and spinal
tumours. Int. J. Epidemiol. 23,
458–464.
Tomlinson, J. W., Holden, N., Hills,
R. K., Wheatley, K., Clayton, R.
N., Bates, A. S., Sheppard, M. C.,
and Stewart, P. M. (2001). Asso-
ciation between premature mor-
tality and hypopituitarism. West
Midlands Prospective Hypopitu-
itary Study Group. Lancet 357,
425–431.
van der Klaauw, A. A., Biermasz, N.
R., Pereira, A. M., van Kralingen,
K. W., Dekkers, O. M., Rabe, K.
F., Smit, J. W., and Romijn, J. A.
(2008). Patients cured from cran-
iopharyngioma or nonfunctioning
pituitary macroadenoma (NFMA)
suffer similarly from increased day-
time somnolence despite normal
sleep patterns compared to healthy
controls. Clin. Endocrinol. (Oxf.) 69,
769–774.
Van Effenterre, R., and Boch, A.
L. (2002). Craniopharyngioma in
adults and children: a study of
122 surgical cases. J. Neurosurg. 97,
3–11.
Van Gaal, L. F., Mertens, I. L., and
De Block, C. E. (2006). Mech-
anisms linking obesity with car-
diovascular disease. Nature 444,
875–880.
Verhelst, J., Kendall-Taylor, P., Erfurth,
E. M., Price, D. A., Geffner, M.,
Koltowska-Haggstrom, M., Jonsson,
www.frontiersin.org March 2012 | Volume 3 | Article 46 | 7
Zoicas and Schöﬂ Craniopharyngiomas in adults
P. J., Wilton, P., and Abs, R. (2005).
Baseline characteristics and response
to 2 years of growth hormone
(GH) replacement of hypopitu-
itary patients with GH deﬁciency
due to adult-onset craniopharyn-
gioma in comparison with patients
with nonfunctioning pituitary ade-
noma: data from KIMS (Pﬁzer
International Metabolic Database).
J. Clin. Endocrinol. Metab. 90,
4636–4643.
Voges, J., Sturm, V., Lehrke, R., Treuer,
H., Gauss, C., and Berthold, F.
(1997). Cystic craniopharyngioma:
long-term results after intracavi-
tary irradiation with stereotacti-
cally applied colloidal beta-emitting
radioactive sources. Neurosurgery
40, 263–269.
Webb, S. M., Rigla, M., Wagner, A.,
Oliver, B., and Bartumeus, F. (1999).
Recovery of hypopituitarism after
neurosurgical treatment of pitu-
itary adenomas. J. Clin. Endocrinol.
Metab. 84, 3696–3700.
Weiner, H. L., Wisoff, J. H., Rosenberg,
M. E., Kupersmith, M. J., Cohen,
H., Zagzag, D., Shiminski-Maher, T.,
Flamm, E. S., Epstein, F. J., and
Miller, D. C. (1994). Craniopharyn-
giomas: a clinicopathological analy-
sis of factors predictive of recur-
rence and functional outcome. Neu-
rosurgery 35, 1001–1010; discussion
1010–1011.
Wisoff, J. H. (1994). Surgical
management of recurrent cran-
iopharyngiomas. Pediatr. Neurosurg.
21(Suppl. 1), 108–113.
Yasargil, M. G., Curcic, M., Kis, M.,
Siegenthaler, G., Teddy, P. J., and
Roth, P. (1990). Total removal
of craniopharyngiomas.Approaches
and long-term results in 144
patients. J. Neurosurg. 73, 3–11.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 29 February 2012; accepted: 11
March 2012; published online: 29 March
2012.
Citation: Zoicas F and Schöﬂ C
(2012) Craniopharyngioma in
adults. Front. Endocrin. 3:46. doi:
10.3389/fendo.2012.00046
This article was submitted to Frontiers
in Pituitary Endocrinology, a specialty of
Frontiers in Endocrinology.
Copyright © 2012 Zoicas and Schöﬂ.This
is an open-access article distributed under
the terms of the Creative Commons Attri-
bution Non Commercial License, which
permits non-commercial use, distribu-
tion, and reproduction in other forums,
provided the original authors and source
are credited.
Frontiers in Endocrinology | Pituitary Endocrinology March 2012 | Volume 3 | Article 46 | 8
